New Haven drug developer Achillion Pharmaceuticals Inc. has promoted its chief medical officer responsible for shepherding through the drug-approval pipeline its roster of treatments against hepatitis C and HIV.
Elizabeth A. Olek M.D. was elevated to senior vice president of clinical development. Olek had been a vice president since joining the company in late 2007.
Achillion Chairman and CEO Michael Kishbauch credits Olek’s “extraordinary talent and leadership” for not only Achillion’s “clinical success to date, but for driving our [drug] pipeline toward the key development milestones anticipated later this year.”
